Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience

Area of Science:

• Vaccinology
• Pandemic Preparedness
• Infectious Disease Control

Background:

• The COVID-19 pandemic necessitated rapid development and deployment of novel vaccine platforms.
• Non-pharmaceutical interventions had severe health and economic consequences, driving a "100-day response ambition" for future pandemics.
• Influenza viruses and novel coronaviruses represent significant future pandemic threats.

Purpose of the Study:

• To assess the role of existing and novel vaccine platforms in pandemic response.
• To evaluate the readiness of influenza vaccine manufacturing for future threats.
• To inform strategies for a "100-day response" to emerging infectious diseases.

Main Methods:

• Review of historical pandemic responses, particularly influenza.
• Analysis of advances in vaccine science and manufacturing capabilities.
• Evaluation of established versus novel vaccine platform utilization.

Main Results:

• COVID-19 demonstrated the potential of new vaccine technologies.
• Established influenza vaccine manufacturing has a proven track record of rapid deployment (e.g., A(H1N1) 2009).
• Significant advancements in vaccine science optimize rapid response capabilities.

Conclusions:

• Both novel and established vaccine platforms are essential for future pandemic preparedness.
• The influenza vaccine manufacturing sector is well-positioned for rapid response.
• Continued investment in vaccine innovation and manufacturing is critical for global health security.